Comparative Pharmacology
Head-to-head clinical analysis: KINEVAC versus THYREL TRH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KINEVAC versus THYREL TRH.
KINEVAC vs THYREL TRH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KINEVAC (sincalide) is a synthetic analog of cholecystokinin (CCK) that stimulates gallbladder contraction and pancreatic secretion by binding to CCK-1 receptors on gallbladder smooth muscle and pancreatic acinar cells, leading to release of bile and pancreatic enzymes.
Synthetic thyrotropin-releasing hormone (TRH) that stimulates the release of thyroid-stimulating hormone (TSH) and prolactin from the anterior pituitary.
KINEVAC (sincalide) is administered as an IV injection or infusion. For gallbladder contraction/cholecystography: 0.02 mcg/kg IV over 30-60 seconds; may repeat once after 15 minutes if inadequate response. For pancreatic function testing: 0.02 mcg/kg IV over 30-60 seconds followed by secretin stimulation.
Adult: 500 mcg IV bolus over 15-30 seconds; may repeat once after 15-30 minutes if needed.
None Documented
None Documented
Terminal elimination half-life is 22 hours (range 15-30 hours) in patients with normal renal function. Clinically, this supports once-daily dosing.
Terminal elimination half-life is approximately 5–6 minutes in healthy adults. This short half-life reflects rapid enzymatic degradation and renal clearance, requiring rapid intravenous administration for diagnostic thyroid stimulation.
Biliary/fecal: >90% as unchanged drug; renal: <5% as metabolites.
Primarily renal excretion of intact TRH and metabolites (deamido-TRH and acid-TRH). Approximately 90% of administered radioactivity is recovered in urine within 24 hours. Biliary/fecal excretion accounts for less than 10%.
Category C
Category C
Diagnostic Agent, Secretin Analog
Diagnostic Agent